Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity

Medical Hypotheses

Volumn 56, Issue 2, 2001, Pages 213-216

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GESTAGEN; PROGESTERONE; SOMATOMEDIN C;

ALZHEIMER DISEASE; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLON CANCER; DRUG POTENTIATION; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0035094755     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.2000.1152     Document Type: Article

References (38)

1. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
2. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
3. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women
4. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause
5. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study
6. Insulin-like growth factor-I and binding protein-3 and risk of cancer
7. Western nutrition and the insulin resistance syndrome: A link to breast cancer
8. Estrogen replacement therapy and colorectal cancer risk in elderly women
9. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
10. Reduced mortality associated with long-term postmenopausal estrogen therapy
11. Effect of progestins on IGF-I serum level in estrogen-treated postmenopausal women
12. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells
13. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer
14. Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women
15. Effect of short-term medroxyprogesterone acetate on left ventricular mass: Role of insulin-like growth factor-I
16. Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy
17. Insulin-dependent regulation of insulin-like growth factor-binding protein-1
18. HRT and breast cancer risk: A clue for interpreting the available data
19. The androgenicity of progestins
20. Micronized progesterone: A new therapeutic option
21. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
22. Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys
23. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys
24. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
25. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
26. Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes
27. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men
28. Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta
29. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
30. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone
31. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women
32. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women
33. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women-a randomised controlled trial
34. Micronized progesterone: Clinical indications and comparison with current treatments
35. Hormone replacement therapy increases the risk of breast cancer
36. Twenty-year review of a breast cancer screening project. Ninety-five percent survival of patients with nonpalpable cancers
37. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project
38. Antiestrogens-tamoxifen, SERMs and beyond